News Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Jan 03, 2023
Mr. Staggs elevated from "interim" to "permanent" CEO as SWK advances multiple initiatives in 2023 Ms. Dotter joined SWK's Board of Directors in February 2022 DALLAS, Jan. 3, 2023 /PRNewswire/ --...
- Nov 16, 2022
SW K Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, announced the...
- Nov 09, 2022
Conference Call and Live Audio Webcast Scheduled for Thursday, November 10, 2022, at 10:00 a.m. ET Corporate Highlights Successful leadership transition with Jody Staggs named President and...
- Nov 08, 2022
Conference Call and Live Audio Webcast Scheduled for Thursday, November 10, 2022, at 10:00 a.m. ET DALLAS, Nov. 8, 2022 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ: SWKH) ("SWK" or the...
- Oct 26, 2022
Oral Presentation Delivered at the American Society for Reproductive Medicine Scientific (ASRM) 2022 Congress & Expo BOONTON, N.J., Oct. 26, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a...
- Oct 18, 2022
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an...
- Oct 10, 2022
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned...
- Oct 03, 2022
Yvette Heinrichson promoted to Chief Financial Officer John David Tamas promoted to Director of Underwriting DALLAS, Oct. 3, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or...
- Sep 12, 2022
Physicochemical properties of peptides can provide key insights to potential success of oral delivery BOONTON, N.J., Sept. 12, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company...
- Sep 07, 2022
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that...
- Sep 01, 2022
Jody Staggs appointed as President and Interim CEO CEO Winston Black will assist in an interim consulting role after successfully establishing SWK Holdings as a leading life science focused...
- Aug 10, 2022
Conference Call and Live Audio Webcast Scheduled for Thursday, August 11, 2022, at 10:00 a.m. ET Corporate Highlights Celebrated 10th anniversary as a life science focused specialty finance...
- Aug 09, 2022
Conference Call and Live Audio Webcast Scheduled for Thursday, August 11, 2022, at 10:00 a.m. ET DALLAS, Aug. 9, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the...
- Aug 03, 2022
Article describes Enteris' strengths and scalability in working with highly potent active pharmaceutical ingredients BOONTON, N.J., August 3, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a...
- Jul 14, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jul 13, 2022
Since 2012, SWK Holdings has completed financings with 46 life sciences companies, deploying $650 million of capital Second Quarter 2022 Financial Results to be Announced in August DALLAS, July...
- Jun 27, 2022
SWK Holdings Corporation (Nasdaq: SWKH), a life science-focused specialty finance company catering to small-and mid-sized commercial-stage companies, announced today its addition to the Russell...
- Jun 13, 2022
Data suggest that oral formulations of leuprolide developed utilizing Enteris' Peptelligence® platform successfully deliver meaningful circulating drug concentrations and achieve hormonal...
- Jun 07, 2022
Facilities and processes key to protecting workers and the environment, the paper in Drug Development & Delivery says BOONTON, N.J., June 7, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a...
- May 26, 2022
Enteris BioPharma, Inc. gave plush animals a dose of personality as they created a dozen stuffed teddy bears for Ronald McDonald House Charities to help comfort sick children as they undergo...
- May 19, 2022
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, announced today that...
- May 11, 2022
In the news release, SWK Holdings Corporation Announces Financial Results for First Quarter 2022, issued 11-May-2022 by SWK Holdings Corporation over PR Newswire, we are advised by the company...
- May 10, 2022
Conference Call and Live Audio Webcast Scheduled for Wednesday, May 11, 2022, at 10:00 a.m. ET DALLAS, May 10, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the...
- May 04, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Apr 12, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Apr 04, 2022
Article describes unique features of Enteris' Peptelligence® and ProPerma® peptide and small molecule oral delivery technology BOONTON, N.J., April 4, 2022 /PRNewswire/ -- Enteris BioPharma,...
- Mar 28, 2022
Conference Call and Live Audio Webcast Scheduled for Monday, March 28, 2022, at 10:00 a.m. ET Corporate Highlights Reconstituted Board and appointed Wendy DiCicco, Robert K. Hatcher, and Laurie Dotter
- Mar 25, 2022
Advanced Oxygen Therapy Inc. (AOTI), the global leader in noninvasive topical oxygen wound healing solutions, announced today they have closed a significant round of growth funding from the...
- Mar 23, 2022
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that...
- Mar 07, 2022
NEWTON, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
- Mar 07, 2022Paper examines barriers to achieving optimal content uniformity with HPAPIs and the techniques manufacturers should use with low-dose drug products
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Mar 02, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Feb 16, 2022
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced the reconstitution of the...
- Feb 15, 2022Six feasibility programs underway for oral tablet formulations developed with Enteris' Peptelligence® and ProPerma® technology platforms
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Feb 09, 2022Fourth Quarter 2021 Financial Results to be Announced in March
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an...
- Jan 10, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jan 05, 2022
SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") today announced that the special committee of the Company's board of directors (the "Special Committee") has concluded its...
- Jan 05, 2022Enteris continues to capitalize on multiple value building opportunities involving Peptelligence® and ProPerma® platforms
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Dec 27, 2021Capital infusion to finance inventory and annual recurring revenue subscriptions replaces expiring debt with more favorable terms
REDWOOD CITY, CA / ACCESSWIRE / December 27, 2021 /Biotricity Inc. (NASDAQ:BTCY) a modern medical technology company delivering innovative, remote biometric monitoring solutions, today announced...
- Dec 20, 2021
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Dec 09, 2021Fourth milestone payment triggered by successful completion of process technology transfer related to the development of Oral KORSUVA™
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned...
- Nov 24, 2021Announces Formation of Special Committee
SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") confirmed that on November 23, 2021, it received a non-binding proposal from funds managed by Carlson Capital, L.P. ("Carlson") to...
- Nov 17, 2021Paper Discusses the 505(b)(2) Pathway as a Vehicle for Innovation and Product Differentiation
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Nov 12, 2021Conference Call and Live Audio Webcast Scheduled for Monday, November 15, 2021 at 10:00 a.m. ET
Corporate Updates Conclusion of strategic review process with SWK to focus on specialty finance receivables business SWK evaluating ongoing dividend and additional leverage Third Quarter 2021...
- Nov 02, 2021Paper Examines the Opportunities and Challenges in Working with High Potency APIs
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Nov 01, 2021Commitment to focus on and grow SWK's core specialty finance business going forward
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided an...
- Oct 26, 2021
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Oct 13, 2021
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Oct 04, 2021Data indicates optimized Peptelligence oral leuprolide formulation delivers comparable or greater drug levels than subcutaneous or depot injection
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Aug 23, 2021Enteris recognized for the third consecutive year in Pharmaceutical Company category
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...